

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	NeuroScientific Biopharmaceuticals Limited
ABN	13 102 832 995

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Stephen Quantrill
Date of last notice	13 December 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	(1) Indirect (2) Indirect
Nature of indirect interest (including registered holder)	(1) Family Trust (2) Family Trust
Date of change	(2) 03 July 2023 and 04 July 2023
No. of securities held prior to change	(1.1) 500,000 - UNLISTED OPTIONS @ \$0.40 EXP 15/01/2024 (1.2) 600,000 - DIRECTOR OPTIONS @ \$0.50 EXP 07/12/2024 (2) 180,000 - ORDINARY FULLY PAID SHARES
Class	(1.1) UNLISTED OPTIONS @ \$0.40 EXP 15/01/2024 (1.2) DIRECTOR OPTIONS @ \$0.50 EXP 07/12/2024 (2) ORDINARY FULLY PAID SHARES
Number acquired	(2) 180,000 ORDINARY FULLY PAID SHARES
Number disposed	NIL
Value/Consideration	(2)\$17,375
No. of securities held after change	(1.1) 500,000 - UNLISTED OPTIONS @ \$0.40 EXP 15/01/2024 (1.2) 600,000 - DIRECTOR OPTIONS @ \$0.50 EXP 07/12/2024 (2) 360,000 - ORDINARY FULLY PAID SHARES

⁺ See [chapter 19](#) for defined terms.

Nature of change	(2) On market purchase
------------------	------------------------

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See [chapter 19](#) for defined terms.